Prosecution Insights
Last updated: October 02, 2026
Application No. 19/402,812

COMPOSITIONS AND METHODS OF USE FOR MODIFIED RELEASE MINOXIDIL

Non-Final OA §112§DOUBLEPATENT
Filed
Nov 26, 2025
Priority
Oct 25, 2022 — provisional 63/419,155 +5 more
Examiner
HENLEY III, RAYMOND J
Art Unit
1629
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
VERADERMICS INCORPORATED
OA Round
2 (Non-Final)
84%
Grant Probability
Favorable
2-3
OA Rounds
1y 0m
Est. Remaining
86%
With Interview

Examiner Intelligence

Grants 84% — above average
84%
Career Allowance Rate
1051 granted / 1258 resolved
+23.5% vs TC avg
Minimal +2% lift
Without
With
+2.3%
Interview Lift
resolved cases with interview
Fast prosecutor
1y 10m
Avg Prosecution
43 currently pending
Career history
1313
Total Applications
across all art units

Statute-Specific Performance

§101
5.9%
-34.1% vs TC avg
§103
21.4%
-18.6% vs TC avg
§102
8.6%
-31.4% vs TC avg
§112
31.4%
-8.6% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1258 resolved cases

Office Action

§112 §DOUBLEPATENT
CLAIMS 1-12 AND 21-28 ARE PRESENTED FOR EXAMINATION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Applicant’s amendment, remarks and Information Disclosure Statement filed July 01, 2026 have been received and entered into the application. As reflected by the attached, completed copies of form PTO/SB/08, the cited references have been considered by the Examiner. Also, the application papers have been amended as directed. Claim Rejection - 35 USC § 112 Claims 12 is rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for the reasons of record as set forth in the previous Office action dated April 01, 2026 as applied to claims 13-20, which reasons are here incorporated by reference. The cancellation of claims 13-20 is noted, however the Examiner inadvertently failed to include claim 12 in the previously rejected claim grouping, i.e., the sub-grouping of claims 13-20 should have correctly read as “12-20”. However, for the reasons previously set forth, it is believed that this claim is also properly rejected. Double Patenting Claims 1-12 and 21-28 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-28 of U.S. Patent No. 12,268,688, (cited by Applicant) in view of Sinha, (U.S. 2024/0474594, (effective 09/29/21 via Prov. Application 63/250,009) and Jordan, (U.S. Patent No. 6,448,323), both cited by the Examiner OR provisionally rejects claims 1-20 on the grounds of nonstatutory double patenting as being unpatentable over claims 1-20 of US Application No. 19/420,555 or claims 1-11 and 21-29 of U.S. Application No. 19/424,027, (now allowed and soon to be patented), for the reasons of record as set forth in the previous Office action, as applied to claims 1-20, which reasons are here incorporated by reference. Applicant’s arguments have been carefully considered, but fail to persuade the Examiner of error. In particular, rather than pointing to any supposed error in the Examiner’s reasons for rejection, Applicant has merely point to that claim 1 has been amended. However, the amendment to claim was formal in nature and did not change the scope thereof. Thus, the claims are deemed properly rejected and none of the claims are currently in condition for allowance. Any inquiry concerning this communication or earlier communications from the examiner should be directed to RAYMOND J HENLEY III whose telephone number is (571)272-0575. The examiner can normally be reached M-F 6-2:30pm EST. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Jeffrey S Lundgren can be reached on 571-272-5541. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /RAYMOND J HENLEY III/Primary Examiner, Art Unit 1629 August 14, 2026
Read full office action

Prosecution Timeline

Nov 26, 2025
Application Filed
Apr 01, 2026
Non-Final Rejection mailed — §112, §DOUBLEPATENT
Jul 01, 2026
Response Filed
Aug 18, 2026
Non-Final Rejection mailed — §112, §DOUBLEPATENT (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12734182
METHODS OF TREATING ISCHEMIC STROKE AT RISK FOR CEREBRAL OR CEREBELLAR EDEMA
1y 1m to grant Granted Sep 15, 2026
Patent 12728103
PHARMACEUTICAL COMPOSITION COMPRISING MITOTANE ADMINISTERED ORALLY FOR TREATMENT OF ADRENOCORTICAL CARCINOMA AND CUSHING'S SYNDROME
3y 0m to grant Granted Sep 08, 2026
Patent 12702665
Exo VII Inhibitor and Quinolone Antibiotic Combination Useful for Treating Bacterial Infection
3y 1m to grant Granted Aug 11, 2026
Patent 12629370
TREATMENT OF PROSTATE CANCER
10m to grant Granted May 19, 2026
Patent 12616752
PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM
11m to grant Granted May 05, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

2-3
Expected OA Rounds
84%
Grant Probability
86%
With Interview (+2.3%)
1y 10m (~1y 0m remaining)
Median Time to Grant
Moderate
PTA Risk
Based on 1258 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month